Quantcast

Latest Novartis AG Stories

2010-10-27 09:44:00

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Novartis announced today that it will add 300 new jobs and invest $600 million over the next five years to expand its global Research headquarters campus on Massachusetts Avenue in Cambridge, Mass. "Novartis was the first global pharmaceutical company to move its Research headquarters to Massachusetts just a few years ago. It has achieved prominence and, we believe, helped to amplify Cambridge's magnetism for others in the biomedical field to...

2010-10-16 15:45:00

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada. The study showed that Reclast maintained bone mass in...

2010-10-07 06:00:00

EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis. Gilenya was approved by the US Food and Drug Administration (FDA) on September 21, 2010. For people with MS and healthcare professionals seeking information about Gilenya, Novartis offers free programs to learn about educational...

2010-09-22 00:30:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. To view the multimedia assets associated with this release,...

2010-09-22 00:27:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine...

2010-09-15 08:31:00

CHICAGO, Sept. 15 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for WMT, CMCSA, GPS, NVS, and CROX. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/091510A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Wal-Mart Stores Inc. (NYSE: WMT), Comcast Corporation (Nasdaq:...

2010-07-27 00:15:00

PARSIPPANY, N.Y., July 27 /PRNewswire/ -- Novartis announces the introduction of Triaminic(TM) Fever Reducer Pain Reliever, the only branded over-the-counter children's liquid acetaminophen product currently available nationwide in the US. Triaminic® now offers parents a product that combines the pain relieving and fever-reducing power of acetaminophen with the brand that has been trusted by pediatricians and parents for more than 50 years. "Given the lack of...

2010-07-14 15:39:00

BASEL, Switzerland, July 14 /PRNewswire/ -- Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG, and Sanford Wittels & Heisler, LLP, Counsel to the Plaintiffs and the Class, have announced an amicable end to their litigation. Today the parties filed papers in the Southern District of New York memorializing a settlement agreement including up to USD 152.5 million in payments to eligible class members and NPC's funding, over three years, of improvements to...

2010-06-28 06:16:00

DALLAS, June 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry the Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Market Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/market-reports/gastrointestinal-disorders-th erapeutics-to-2016-high-unmet-need/ GBI Research's report, "Gastrointestinal disorders therapeutics,...

2010-06-10 19:15:00

EAST HANOVER, N.J., June 10 /PRNewswire/ -- Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related